Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study-Reference-Cited by-同舟云学术

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Published:2020-04-13 Issue:5 Volume:13 Page:972-984
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Jarmusch Alan K.¹,Vrbanac Alison²,Momper Jeremiah D.³,Ma Joseph D.³,Alhaja Maher³,Liyanage Marlon³,Knight Rob²⁴⁵,Dorrestein Pieter C.¹²⁴,Tsunoda Shirley M.³

Affiliation:

1. Skaggs School of Pharmacy and Pharmaceutical Sciences and Collaborative Mass Spectrometry Innovation Center University of California, San Diego La Jolla California USA

2. Department of Pediatrics University of California, San Diego La Jolla California USA

3. Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego La Jolla California USA

4. Center for Microbiome Innovation University of California, San Diego La Jolla California USA

5. Department of Computer Science and Engineering University of California, San Diego La Jolla California USA

Funder

National Institutes of Health

Tsunoda

Center for Computational Mass Spectrometry

P.C.D.

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12785

Reference49 articles.

1. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?

2. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil

3. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5‐fluorouracil prodrugs;Okuda H.;J. Pharmacol. Exp. Ther.,1998

4. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism

5. Gut microbiome modulates response to anti‐PD‐1 immunotherapy in melanoma patients;Gopalakrishnan V.;Science,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibiotics affect the pharmacokinetics of n-butylphthalide in vivo by altering the intestinal microbiota;PLOS ONE;2024-06-25

2. Bioengineered human gut-on-a-chip for advancing non-clinical pharmaco-toxicology;Expert Opinion on Drug Metabolism & Toxicology;2024-06-24

3. Antibiotics affect the pharmacokinetics of n-butylphthalidein vivoby altering the intestinal microbiota;2024-01-14

4. The changes of gut microbiota and metabolites in different drug-induced liver injuries;Journal of Medical Microbiology;2023-11-28

5. Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage;Journal of Advanced Research;2023-10